Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : AMX-818
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Sanofi
Deal Size : Undisclosed
Deal Type : Acquisition
Sanofi Completes Acquisition of Amunix
Details : The acquisition also provides access to Amunix Pro-XTEN, XPAT, and XPAC technology to deliver next generation Conditionally Activated Biologics. The technology platform is highly complementary to Sanofi’s existing R&D platforms.
Brand Name : AMX-818
Molecule Type : Large molecule
Upfront Cash : Undisclosed
February 08, 2022
Lead Product(s) : AMX-818
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Sanofi
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : AMX-818
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Sanofi
Deal Size : $1,225.0 million
Deal Type : Acquisition
Details : Under the terms of the agreement, Sanofi will acquire Amunix with it's pipeline including it's lead candidate, AMX-818, a masked HER2-directed TCE, offers a strong strategic fit with Sanofi’s focus on developing potentially transformative cancer therap...
Brand Name : AMX-818
Molecule Type : Large molecule
Upfront Cash : $1,000.0 million
December 21, 2021
Lead Product(s) : AMX-818
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Sanofi
Deal Size : $1,225.0 million
Deal Type : Acquisition
Lead Product(s) : AMX-818
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : AMX-818, a protease-activated T cell engager targeting HER2 with potent T Cell activation, proteolytic cleavage and efficacy in Xenograft tumors.
Brand Name : AMX-818
Molecule Type : Large molecule
Upfront Cash : Not Applicable
October 07, 2021
Lead Product(s) : AMX-818
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : AMX-818
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Data demonstrate potential of Amunix’s XPAT platform to significantly widen therapeutic index, and address on-target, off-tumor toxicity that has hindered application of T cell engagers to treat solid tumors.
Brand Name : AMX-818
Molecule Type : Large molecule
Upfront Cash : Not Applicable
June 22, 2020
Lead Product(s) : AMX-818
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : AMX-818
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Omega Funds
Deal Size : $73.0 million
Deal Type : Series A Financing
Amunix Raises $73 Million in Series A Financing Led by Omega Funds
Details : Amunix plans to utilize the Series A proceeds to advance its lead development candidate, AMX-818, to progress earlier discovery stage XPAT programs and to initiate XPAC discovery work.
Brand Name : Undisclosed
Molecule Type : Cell and Gene therapy
Upfront Cash : Undisclosed
March 04, 2020
Lead Product(s) : AMX-818
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Omega Funds
Deal Size : $73.0 million
Deal Type : Series A Financing
Lead Product(s) : Polypeptides
Therapeutic Area : Oncology
Study Phase : Undisclosed
Sponsor : F. Hoffmann-La Roche
Deal Size : $1,540.0 million
Deal Type : Licensing Agreement
Details : This agreement builds on Amunix’s previous technology assessment with Roche focused on using XTEN, a proprietary unstructured polypeptide, to extend drug half-life.
Brand Name : Undisclosed
Molecule Type : Peptide
Upfront Cash : $40.0 million
January 10, 2020
Lead Product(s) : Polypeptides
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Sponsor : F. Hoffmann-La Roche
Deal Size : $1,540.0 million
Deal Type : Licensing Agreement